viewAmryt Pharma PLC

Hybridan’s Pearson cautions biotech investors against knee-jerk reactions to drug trial blips

Hybridan’s Niall Pearson tells biotech investors that drug trial failure is ‘the nature of the beast’ and speaking with Proactive Investors he highlighted examples where selling has gone too far.

“When companies have them [trial failures] there’s a big hooha and everyone forgets what they are actually investing in,” Pearson said.

The broker notes Circassia - which recently plummeted more than 60% as a cat allergy treatment trial disappointed - as an example where the market showed a knee-jerk reaction.

Pearson also talked about the ‘long game’ of regaining trust, the importance of diversification, and the opportunities for investing in companies developing drugs for rare diseases and conditions where there are unmet medical needs.

One such example identified by Pearson is Amryt Pharma Plc (LONLAMYT) - a recent addition to the market that will certainly be familiar to avid followers of Proactive Investors.

Quick facts: Amryt Pharma PLC

Price: 196 GBX

Market: AIM
Market Cap: £302.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...



Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

2 min read